Staged treatment of ovarian cancer in a patient: Therapeutic strategy and outcomes

  • Received 11.09.2025

  • Revised 22.01.2026

  • Accepted 24.02.2026

  • Published 25.03.2026


  • 196 Views

  • Retrieved from Vol. 8, No. 1, 2026

  • Pages 8-16

Epithelial ovarian cancer remains one of the most aggressive gynaecological malignancies, which in most cases is diagnosed at advanced stages. The aim of the study was to present a staged treatment of a patient with advanced high-grade serous ovarian carcinoma, demonstrating the value of multimodal diagnostics, laparoscopic determination of the peritoneal carcinomatosis index, assessment of morphological response, and integrated chemo-surgical tactics in accordance with the ESGO/ESMO 2023 recommendations. A 45-year-old patient with bilateral ovarian lesions, ascites, and a high carcinomatosis index (24) underwent a comprehensive examination that included ultrasound, computed tomography, magnetic resonance imaging, endoscopic methods, laparoscopy with biopsy, and in-depth morphological analysis (histology, immunohistochemistry, assessment of Ki-67, estrogen receptor expression, and angiogenic markers). Pathohistological examination demonstrated a high degree of therapeutic pathomorphosis: a sharp decrease in Ki-67 (up to 2-5%), single tumour cells against a background of pronounced fibrosis, a decrease in microvascular density and the presence of xanthoma cells in areas of previous necrosis. Postoperative adjuvant treatment provided a stable response without signs of progression. The treatment results demonstrated the effectiveness of a staged treatment strategy for advanced ovarian cancer, which combined laparoscopic assessment of resectability, neoadjuvant polychemotherapy, interval cytoreduction and morphological verification of the response. The results obtained confirmed the high prognostic informativeness of the carcinomatosis index, Ki-67 and morphological markers of regression. The findings of the work can be used by gynaecological oncologists, chemotherapists, and pathologists in specialised oncology and university clinics when planning and assessing the effectiveness of staged treatment of advanced epithelial ovarian cancer

neoadjuvant chemotherapy; cytoreduction; peritoneal carcinomatosis; adenocarcinoma; paclitaxel; carboplatin

https://doi.org/10.63341/bmbr/1.2026.08
  1. Caruso G, Weroha SJ, Cliby W. Ovarian cancer: A review. JAMA. 2025;334(14):1278–91. DOI: 10.1001/jama.2025.9495
  2. Gaona-Luviano P, Medina-Gaona LA, Magaña-Pérez K. Epidemiology of ovarian cancer. Chin Clin Oncol. 2020;9(4):47. DOI: 10.21037/cco-20-34
  3. Zamwar UM, Anjankar AP. Aetiology, epidemiology, histopathology, classification, detailed evaluation, and treatment of ovarian cancer. Cureus. 2022;14(10):e30561. DOI: 10.7759/cureus.30561
  4. Nag S, Aggarwal S, Rauthan A, Warrier N. Maintenance therapy for newly diagnosed epithelial ovarian cancer – a review. J Ovarian Res. 2022;15:88. DOI: 10.1186/s13048-022-01020-1
  5. Ali AT, Al-Ani O, Al-Ani F. Epidemiology and risk factors for ovarian cancer. Menopause Rev. 2023;22(2):93–104. DOI: 10.5114/pm.2023.128661
  6. Zhou L, Yao L, Dai L, Zhu H, Ye X, Wang S, et al. Ovarian endometrioid carcinoma and clear cell carcinoma: A 21-year retrospective study. J Ovarian Res. 2021;14:63. DOI: 10.1186/s13048-021-00804-1
  7. Tavares V, Marques IS, de Melo IG, Assis J, Pereira D, Medeiros R. Paradigm shift: A comprehensive review of ovarian cancer management in an era of advancements. Int J Mol Sci. 2024;25(3):1845. DOI: 10.3390/ijms25031845
  8. González-Martín A, Harter P, Leary A, Lorusso D, Miller RE, Pothuri B, et al. Newly diagnosed and relapsed epithelial ovarian cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023;34(10):833–48. DOI: 10.1016/j.annonc.2023.07.011
  9. Berek JS, Renz M, Kehoe S, Kumar L, Friedlander M. Cancer of the ovary, fallopian tube, and peritoneum: 2021 update. Int J Gynaecol Obstet. 2021;155(1):61–85. DOI: 10.1002/ijgo.13878
  10. Macchia G, Titone F, Restaino S, Arcieri M, Pellacchia G, Andreetta C, et al. Is it time to reassess the role of radiotherapy treatment in ovarian cancer? Healthcare. 2023;11(17):2413. DOI: 10.3390/healthcare11172413
  11. Chyzhma RA, Nykolenko AP, Piddubnyi AM, Moskalenko RA. Analysis of the malignant ovarian tumors incidence in the Sumy region in 2014-2018. Morphologia. 2021;15(1):73–8. DOI: 10.26641/1997-9665.2021.1.73-78
  12. Fedorenko Z, Mykhailovych Yu, Goulak L, Gorokh Ye, Ryzhov A, Soumkina O, et al. Cancer in Ukraine 2018-2019: Incidence, mortality, activities of oncological service. Kyiv: National Cancer Institute of Ukraine; 2020. 84 P.
  13. WMA Declaration of Helsinki – Ethical Principles for Medical Research Involving Human Participants [Internet]. 2024 October 19 [cited 2025 July 20]. Available from: https://www.wma.net/policies-post/wma-declaration-of-helsinki/
  14. Order of the Ministry of Health of Ukraine No. 845. On the System of Oncological Care for the Population of Ukraine [Internet]. 2013 October 1 [cited 2025 July 20]. Avaliable from: https://zakon.rada.gov.ua/laws/show/z0077-14#Text
  15. Ledermann JA, Matias-Guiu X, Amant F, Concin N, Davidson B, Fotopoulou C, et al. ESGO-ESMO-ESP consensus conference recommendations on ovarian cancer: Pathology and molecular biology and early, advanced and recurrent disease. Ann Oncol. 2024;35(3):248–66. DOI: 10.1016/J.ANNONC.2023.11.015
  16. Webb PM, Jordan SJ. Global epidemiology of epithelial ovarian cancer. Nat Rev Clin Oncol. 2024;21:389–400. DOI: 10.1038/s41571-024-00881-3
  17. Wang M, Bi Y, Jin Y, Zheng ZJ. Global incidence of ovarian cancer according to histologic subtype: A population-based cancer registry study. JCO Glob Oncol. 2024;10:e2300393. DOI: 10.1200/GO.23.00393
  18. Tew WP, Lacchetti C, Gaillard S. Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: ASCO guideline clinical insights. JCO Oncol Pract. 2025;21(7):932–5. DOI: 10.1200/OP-24-00999
  19. Hayek J, An A, Wolf J, Lamiman K, Kim M, Knochenhauer H, et al. Overall survival following interval complete gross resection of advanced ovarian cancer via laparoscopy versus open surgery: An analysis of the National Cancer Database. J Clin Med. 2025;14(4):1164. DOI: 10.3390/JCM14041164
  20. Piedimonte S, Mohamed M, Rosa G, Gersti B, Vicus D. Predicting response to treatment and survival in advanced ovarian cancer using machine learning and radiomics: A systematic review. Cancers. 2025;17(3):336. DOI: 10.3390/CANCERS17030336
  21. Porter JM, McFarlane I, Bartos C, Churchman M, May J, Herrington CS, et al. The survival benefit associated with complete macroscopic resection in epithelial ovarian cancer is histotype specific. JNCI Cancer Spectr. 2024;8(4):pkae049. DOI: 10.1093/JNCICS/PKAE049
  22. Norppa N, Staff S, Helminen M, Auranen A, Saarelainen S. Improved survival after implementation of ultra-radical surgery in advanced epithelial ovarian cancer: Results from a tertiary referral center. Gynecol Oncol. 2022;165(3):478–85. DOI: 10.1016/J.YGYNO.2022.03.023
  23. Wan S, Su C, Wang Y, Ding J, Jiang Q, Ding H, et al. Prognostic value of Ki-67 in patients with ovarian cancer. Eur J Gynaecol Oncol. 2025;46(1):76–81. DOI: 10.22514/EJGO.2023.051
  24. Böhm S, Le N, Lockley M, Brockbank E, Faruqi A, Said I, et al. Histopathologic response to neoadjuvant chemotherapy as a prognostic biomarker in tubo-ovarian high-grade serous carcinoma: Updated chemotherapy response score (CRS) results. Int J Gynecol Cancer. 2019;29(2):353–6. DOI: 10.1136/IJGC-2018-000092
  25. Kim KI, Lee KH, Kim TR, Chun YS, Lee TH, Park HK. Ki-67 as a predictor of response to neoadjuvant chemotherapy in breast cancer patients. J Breast Cancer. 2014;17(1):40–6. DOI: 10.4048/JBC.2014.17.1.40
  26. Fagotti A, Ferrandina MG, Vizzielli G, Pasciuto T, Fanfani F, Gallota V, et al. Randomized trial of primary debulking surgery versus neoadjuvant chemotherapy for advanced epithelial ovarian cancer (SCORPION-NCT01461850). Int J Gynecol Cancer. 2020;30(11):1657–64. DOI: 10.1136/IJGC-2020-001640
  27. Vergote I, Coens C, Nankivell M, Kristensen GB, Parmar MKB, Ehlen T, et al. Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: Pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials. Lancet Oncol. 2018;19(12):1680–7. DOI: 10.1016/S1470-2045(18)30566-7